Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2024 · 10-Q
Revenue$176.00K$176.00K−40.7% vs Q1 2023 Net Income-$9.13M-$9.13MN/M vs Q1 2023 EPS Diluted-$1.13-$1.13N/M vs Q1 2023 Gross Profit$45,000+350.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$3,830,000N/M Free Cash Flowderived-$3,854,000— Margins · derivedGross margin25.6%+22.2 pt vs Q1 2023
Operating margin-5265.3%
Net margin-5186.9%
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end